Verastem, Inc.

VSTM · Nasdaq · United States

Share price · VSTM

$6.87-0.56 (-7.54%) 3M

close as of 2026-11-18 · 24h delayed · vol 4.0M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VSTM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026-10.3%
  2. 22 Oct 2026+9.2%
  3. 15 Oct 2026+19.7%
  4. 13 Oct 2026-9.7%
  5. 7 Oct 2026+6.6%
  6. 7 Aug 2026+14.0%
  7. 1 Jul 2026+7.3%
  8. 25 Jun 2026-10.4%
  9. 24 Jun 2026-8.6%
  10. 8 May 2026-13.6%

Share of unusual movement by asset

For each asset, the share of VSTM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
GFH375
events and moves
106%
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack) (Avmapki Fakzynja Co-Pack)
events and moves
82%
Other company news (earnings, financing, releases naming no asset)—19%
Sessions with no dated event—72%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
MEK1/2 and RAF (CRAF, BRAF) · FAKSmall molecule
Ovarian Cancer
Phase 3
KRAS G12DSmall molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (7)
April 2027 (1)
GFH375Phase 2NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2027-04-30 · NCT07554859 · CT.gov ↗
What to watch
June 2027 (4)
GFH375Phase 2Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Est. primary completion 2027-06 · NCT07644559 · CT.gov ↗
What to watch
GFH375Phase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-06 · NCT07659782 · CT.gov ↗
What to watch
GFH375Phase 2Colorectal Cancer
Est. primary completion 2027-06 · NCT07659795 · CT.gov ↗
What to watch
GFH375Phase 3Metastatic Pancreatic Cancer
Est. primary completion 2027-06 · NCT07262567 · CT.gov ↗
What to watch
July 2027 (1)
GFH375Phase 1/2Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
Est. primary completion 2027-07 · NCT07259590 · CT.gov ↗
What to watch
August 2027 (1)
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 2Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Est. primary completion 2027-08-01 · NCT07747506 · CT.gov ↗
What to watch
2028 (5)
July 2028 (1)
GFH375Phase 1/2KRAS G12D Mutations, Advanced Solid Tumors
Est. primary completion 2028-07-31 · NCT06500676 · CT.gov ↗
What to watch
August 2028 (1)
GFH375Phase 2Pancreatic Cancer
Est. primary completion 2028-08-31 · NCT07784374 · CT.gov ↗
What to watch
October 2028 (1)
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 3Low Grade Serous Ovarian Cancer
Est. primary completion 2028-10-15 · NCT06072781 · CT.gov ↗
What to watch
November 2028 (1)
GFH375Phase 3Colorectal Cancer
Est. primary completion 2028-11 · NCT07913360 · CT.gov ↗
What to watch
December 2028 (1)
GFH375 + Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 1/2Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
GFH375Phase 3KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)
Est. primary completion 2030-06-30 · NCT07668752 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 June 2026Topline resultAvutometinib/defactinib (Avmapki Fakzynja Co-Pack)RAMP 205 updated results in first-line metastatic pancreatic cancer

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$24M$69M$173M$75M-$34M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$41M$137M+ $0.1M short-term inv.$35M-$44M operating cash flowreport ↗
2026-Q1—$38M$166M+ $16M short-term inv.$37M-$52M operating cash flowreport ↗
2025-Q4$18M$32M$205M$33Mreport ↗
2025-Q3—$29M$138M$99M-$36M operating cash flowreport ↗
2025-Q2—$25M$165M$26M-$33M operating cash flowreport ↗
2025-Q1—$29M$118M+ <$0.1M short-term inv.$52M-$39M operating cash flowreport ↗
2024-Q3—$25M$113M+ <$0.1M short-term inv.$24M-$24M operating cash flowreport ↗
2024-Q2$10M$18M$84M+ <$0.1M short-term inv.$8.3M-$28M operating cash flowreport ↗
2024-Q1—$18M$83M+ $29M short-term inv.$34M-$28M operating cash flowreport ↗
2023-Q3—$14M$97M+ $71M short-term inv.$20M-$17M operating cash flowreport ↗
2023-Q2—$13M$184M+ <$0.1M short-term inv.$24M-$20M operating cash flowreport ↗
2023-Q1—$12M$99M+ $14M short-term inv.$16M-$20M operating cash flowreport ↗
2022-Q3—$11M$79M+ $26M short-term inv.$18M-$15M operating cash flowreport ↗
2022-Q2—$15M$64M+ $30M short-term inv.$22M-$13M operating cash flowreport ↗
2022-Q1$2.6M$14M$47M+ $60M short-term inv.$17M-$19M operating cash flowreport ↗
2021-Q3$0$9.3M$25M+ $79M short-term inv.$23M-$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$31M$115M$205M$210Mreport ↗

Verastem reported full-year 2025 revenue of $30.9M, with prior-year revenue not disclosed. R&D spend was $114.6M, up 41.0% YoY from $81.3M, while cash and equivalents stood at $205M as of December 31, 2025. Quarterly net burn was reported at $209.5M, and no net income or loss figure was disclosed.

The company guided to a cash runway into the first half of 2027 and said the LGSOC commercial launch and development program should become self-sustaining by the second half of 2026. Clinical priorities include an interim update on the VS-7375 Phase 1/2 trial in 1H 2026, a topline readout from the fully enrolled RAMP 301 Phase 3 trial in mid-2027, and a RAMP 205 expansion update in Q2 2026. Updated RAMP 201J data showed a confirmed ORR of 38% overall, including 57% in KRAS-mutated LGSOC patients. The company also noted the exercise of outstanding cash warrants, netting $29.4M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$10M$81M$89M$33M-$105M operating cash flowreport ↗
2023-FY—$61M$79M+ $59M short-term inv.$22M-$86M operating cash flowreport ↗
2022-FY$2.6M$51M$76M+ $13M short-term inv.$18M-$64M operating cash flowreport ↗
2021-FY$2.0M$39M$21M+ $79M short-term inv.$18M-$54M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 32 sales ($1.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03Paterson Dan · director, President and CEOOpen-market sale1,299$9.60$12KForm 4
2026-10-01Calkins Daniel · Chief Financial OfficerOpen-market sale2,566$8.00$21KForm 4
2026-10-01Paterson Dan · director, President and CEOOpen-market sale44,121$8.00$353KForm 4
2026-09-30Calkins Daniel · Chief Financial OfficerAward / grant8,333——Form 4
2026-09-30Paterson Dan · director, President and CEOAward / grant106,893——Form 4
2026-09-21Calkins Daniel · Chief Financial OfficerOpen-market sale55$7.70$424Form 4
2026-08-03Paterson Dan · director, President and CEOOpen-market sale1,302$5.81$8KForm 4
2026-06-22Calkins Daniel · Chief Financial OfficerOpen-market sale4,032$4.18$17KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 155 reporting institutions held 81.4M shares ($428.4M, 64.6% of shares outstanding).

#InstitutionSharesValue
1RTW INVESTMENTS, LP6,576,306$34.9M
2BlackRock, Inc.6,194,925$32.8M
3Deep Track Capital, LP5,740,850$30.4M
4ARMISTICE CAPITAL, LLC4,592,000$24.3M
5Nantahala Capital Management, LLC3,584,820$19.0M
6STATE STREET CORP3,516,651$18.6M
7VANGUARD CAPITAL MANAGEMENT LLC3,322,770$17.6M
8Stonepine Capital Management, LLC3,302,300$17.5M
9Foresite Capital Management VI LLC3,146,631$16.7M
10MILLENNIUM MANAGEMENT LLC2,411,965$12.8M
11CITADEL ADVISORS LLC2,308,669$12.2M
12MORGAN STANLEY2,247,273$11.9M
13Rosalind Advisors, Inc.2,138,475$11.3M
14Alyeska Investment Group, L.P.2,050,000$10.9M
15AIGH Capital Management LLC2,000,000$10.6M